We have located links that may give you full text access.
Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.
New England Journal of Medicine 2018 November 9
In November 2017, the Food and Drug Administration (FDA) required labeling changes for the commercially marketed programmed cell death 1 (PD-1) inhibitor pembrolizumab and the thalidomide-analogue immunomodulatory agents. These changes included information regarding increased mortality observed in..
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app